# A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

> **NCT06419374** · PHASE3 · RECRUITING · sponsor: **89bio, Inc.** · enrollment: 762 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

## Interventions

- **BIOLOGICAL:** Pegozafermin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06419374
- **Lead sponsor:** 89bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2028-06
- **Final completion:** 2031-08
- **Target enrollment:** 762 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06419374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06419374, "A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06419374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*